

Marjolijn Duijm-de Carpentier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9612403/publications.pdf>

Version: 2024-02-01

9
papers

453
citations

1307594

7
h-index

1474206

9
g-index

9
all docs

9
docs citations

9
times ranked

660
citing authors

#	ARTICLE	IF	CITATIONS
1	Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial. <i>Nature Communications</i> , 2020, 11, 3083.	12.8	173
2	Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05). <i>Journal of the National Cancer Institute</i> , 2018, 110, 40-48.	6.3	138
3	Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR+ Early-stage Breast Cancer for 10 Years of Endocrine Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 311-319.	7.0	58
4	Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT (BOOG 2013-14) trial. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 741-758.	2.5	27
5	Tumor-stroma ratio is associated with Miller-Payne score and pathological response to neoadjuvant chemotherapy in HER2-negative early breast cancer. <i>International Journal of Cancer</i> , 2021, 149, 1181-1188.	5.1	24
6	Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials. <i>Journal of Clinical Oncology</i> , 2020, 38, 3273-3281.	1.6	20
7	Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer. <i>European Journal of Cancer</i> , 2018, 95, 59-67.	2.8	7
8	Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 413-420.	2.5	5
9	Predictive performance of breast cancer index (BCI) and clinical treatment score post-5 years (CTS5) in the IDEAL study. <i>Journal of Clinical Oncology</i> , 2022, 40, 545-545.	1.6	1